Journal
NATURE BIOTECHNOLOGY
Volume 28, Issue 2, Pages 157-159Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nbt.1601
Keywords
-
Categories
Funding
- NIDDK NIH HHS [R01 DK056597, R01 DK056597-07] Funding Source: Medline
Ask authors/readers for more resources
Improved affinity for the neonatal Fc receptor (FcRn) is known to extend antibody half-life in vivo. However, this has never been linked with enhanced therapeutic efficacy. We tested whether antibodies with half-lives extended up to fivefold in human (h) FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing intervals. We observed that prolonged exposure due to FcRn-mediated enhancement of half-life improved antitumor activity of Fc-engineered antibodies in an hFcRn/Rag1(-/-) mouse model. This bridges the demand for dosing convenience with the clinical necessity of maintaining efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available